Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) news covers a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals. The company’s updates frequently highlight progress across its crofelemer programs, regulatory interactions, and partnerships.
Investors following JAGX news can expect coverage of developments related to Mytesi, Napo Pharmaceuticals’ FDA-approved crofelemer product for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, as well as Jaguar’s broader intestinal failure program targeting rare disorders such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). News items often describe clinical trial milestones, proof-of-concept data on reductions in parenteral support, and discussions with regulators about potential expedited approval pathways for ultrarare pediatric indications.
On the animal health side, Jaguar news includes information about Canalevia-CA1, the company’s conditionally approved crofelemer-based prescription drug for chemotherapy-induced diarrhea in dogs, along with regulatory grants, conditional approval renewals, and studies designed to support full approval. Updates may also address efforts to obtain guidance from the European Medicines Agency for Canalevia in general diarrhea in dogs.
Corporate and capital markets announcements are another key component of JAGX news. These can include securities purchase agreements, royalty interest amendments, PIPE financings, preferred stock exchanges, and at-the-market offering amendments, as disclosed in Form 8-K filings. Conference presentations, investor summit appearances, and summaries of stockholder meeting results also appear in the company’s news flow.
For investors and observers, the Jaguar Health news page provides a centralized view of clinical, regulatory, commercial, and financing developments that shape the company’s strategy in plant-based gastrointestinal therapeutics for both human and veterinary medicine.
Jaguar Health (NASDAQ:JAGX) announced a Memorandum of Understanding (MOU) with the Dragon SPAC to enable Napo EU’s anticipated listing on AIM Italia. The focus is on seeking conditional marketing authorization for crofelemer to treat inflammatory diarrhea in long-hauler COVID-19 patients in Europe. The partnership aims to leverage Napo's experience in developing plant-based drugs, particularly crofelemer, which is currently used for noninfectious diarrhea in HIV/AIDS patients. The potential market includes 20-70 million people in Europe suffering from gastrointestinal issues related to long COVID.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a webcast on January 27, 2021, at 8:30 AM ET to discuss updates on the proposed merger of its anticipated subsidiary Napo EU with a special purpose acquisition company (SPAC) focused on Post Pandemic Recovery. Jaguar is exploring conditional marketing authorization in Europe for crofelemer, aimed at addressing gastrointestinal issues in long-hauler COVID-19 patients. The webcast will feature CEO Lisa Conte and Andreea Porcelli as co-presenters.
Jaguar Health, Inc. (NASDAQ:JAGX) announced the granting of nonstatutory stock options to new employees as inducement awards. Effective December 9, 2020, one employee received options for 1,500 shares, while another received options for 35,000 shares, with an exercise price of $0.353. Additionally, on January 7, 2021, another employee was granted options for 7,000 shares at $2.68 per share. All options vest over three years, subject to continued employment. These options are part of the Company's strategy to attract and retain talent.
Jaguar Health, Inc. (NASDAQ:JAGX) announced on January 21, 2021, that it has regained compliance with Nasdaq's bid price requirement, as stated by the Nasdaq Hearings Panel on October 28, 2020. CEO Lisa Conte expressed satisfaction with this achievement, attributing it to the company's efforts since Q2 2020, such as expanding patient access to Mytesi® and securing a $6 million royalty-based capital infusion. The company is also advancing a Phase 3 clinical trial for crofelemer aimed at treating cancer therapy-related diarrhea.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a webcast on January 27, 2021, at 8:30 AM ET regarding its potential merger with Post Pandemic Recovery Equity SPAC. Lisa Conte, CEO of Jaguar, and Andreea Porcelli, SPAC sponsor and CEO of Swiss Growth Forum, will co-present updates. The company aims to explore conditional marketing authorization in Europe for its product addressing gastrointestinal distress related to long COVID. Mytesi, Jaguar's FDA-approved medication, is positioned to aid patients suffering from ongoing symptoms post-COVID-19.
Jaguar Health, Inc. (NASDAQ:JAGX) announced the successful issuance of a $6 million secured promissory note to Streeterville Capital, LLC. The financing supports the development of lechlemer, aimed at treating diarrhea and dehydration in cholera patients. The investor holds a right to 18% of gross proceeds from a potential tropical disease priority review voucher (TDPRV). This program incentivizes drug development for neglected diseases and has seen previous vouchers sold for up to $350 million. Napo Pharmaceuticals, Jaguar's subsidiary, is conducting ongoing preclinical studies for lechlemer, which is derived from the Croton lechleri tree.
Jaguar Health, Inc. (NASDAQ:JAGX) has released a recap of its January 14, 2021 investor webcast and provided a replay link due to high participation. Key highlights include plans to pursue conditional marketing authorization in Europe for crofelemer, aimed at treating 'long-hauler' COVID-19 symptoms. The company announced a securities purchase agreement, raising approximately $15 million, and a $6 million agreement related to Napo's lechlemer drug candidate. Jaguar also discussed establishing Napo EU in Italy, targeting additional value from potential licensing arrangements.
Jaguar Health announced a $6 million non-dilutive financing arrangement involving the sale of partial rights to a Tropical Disease Priority Review Voucher (TDPRV). This financing aims to support the clinical development of lechlemer for alleviating diarrhea in cholera patients. The TDPRV, previously valued between $67 million and $350 million, incentivizes drug development for neglected and rare diseases. The company has established that funds from this deal will fully cover the lechlemer clinical program, which is expected to advance clinical trials following positive initial studies.
Jaguar Health, Inc. (NASDAQ:JAGX) has entered a securities purchase agreement with two institutional investors for the sale of 4,437,870 shares of common stock at $3.38 per share, aiming for gross proceeds of approximately $15 million. The offering, scheduled to close around January 15, 2021, is executed under a shelf registration statement effective since September 23, 2020. Ladenburg Thalmann acts as the exclusive placement agent. The funds will be used to support the company's development of plant-based medicines for GI distress, specifically targeting chronic diarrhea.
Jaguar Health, Inc. (NASDAQ:JAGX) announces that CEO Lisa Conte will present at the H.C. Wainwright BIOCONNECT 2021 virtual conference from January 11-14, 2021, with a presentation available on-demand. Additionally, Conte will speak at the NobleCon17 on January 19, 2021, at 4:30 PM Eastern Time. An investor webcast will also be hosted on January 14, 2021, at 11:30 AM Eastern Time. The company plans to explore conditional marketing for crofelemer, targeting post-COVID-19 recovery patients. More details and registration links are provided.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
